187 related articles for article (PubMed ID: 37316681)
1. Tofersen: First Approval.
Blair HA
Drugs; 2023 Jul; 83(11):1039-1043. PubMed ID: 37316681
[TBL] [Abstract][Full Text] [Related]
2. Breaking barriers with tofersen: Enhancing therapeutic opportunities in amyotrophic lateral sclerosis.
Saini A; Chawla PA
Eur J Neurol; 2024 Feb; 31(2):e16140. PubMed ID: 37975798
[TBL] [Abstract][Full Text] [Related]
3. Phase 1-2 Trial of Antisense Oligonucleotide Tofersen for
Miller T; Cudkowicz M; Shaw PJ; Andersen PM; Atassi N; Bucelli RC; Genge A; Glass J; Ladha S; Ludolph AL; Maragakis NJ; McDermott CJ; Pestronk A; Ravits J; Salachas F; Trudell R; Van Damme P; Zinman L; Bennett CF; Lane R; Sandrock A; Runz H; Graham D; Houshyar H; McCampbell A; Nestorov I; Chang I; McNeill M; Fanning L; Fradette S; Ferguson TA
N Engl J Med; 2020 Jul; 383(2):109-119. PubMed ID: 32640130
[TBL] [Abstract][Full Text] [Related]
4. From Failure to Meet the Clinical Endpoint to U.S. Food and Drug Administration Approval: 15th Antisense Oligonucleotide Therapy Approved Qalsody (Tofersen) for Treatment of
van Roon-Mom W; Ferguson C; Aartsma-Rus A
Nucleic Acid Ther; 2023 Aug; 33(4):234-237. PubMed ID: 37581487
[No Abstract] [Full Text] [Related]
5. Profiling tofersen as a treatment of superoxide dismutase 1 amyotrophic lateral sclerosis.
Oliveira Santos M; de Carvalho M
Expert Rev Neurother; 2024 Jun; 24(6):549-553. PubMed ID: 38758193
[TBL] [Abstract][Full Text] [Related]
6. Trial of Antisense Oligonucleotide Tofersen for
Miller TM; Cudkowicz ME; Genge A; Shaw PJ; Sobue G; Bucelli RC; Chiò A; Van Damme P; Ludolph AC; Glass JD; Andrews JA; Babu S; Benatar M; McDermott CJ; Cochrane T; Chary S; Chew S; Zhu H; Wu F; Nestorov I; Graham D; Sun P; McNeill M; Fanning L; Ferguson TA; Fradette S;
N Engl J Med; 2022 Sep; 387(12):1099-1110. PubMed ID: 36129998
[TBL] [Abstract][Full Text] [Related]
7. Neurofilament light-chain response during therapy with antisense oligonucleotide tofersen in SOD1-related ALS: Treatment experience in clinical practice.
Meyer T; Schumann P; Weydt P; Petri S; Koc Y; Spittel S; Bernsen S; Günther R; Weishaupt JH; Dreger M; Kolzarek F; Kettemann D; Norden J; Boentert M; Vidovic M; Meisel C; Münch C; Maier A; Körtvélyessy P
Muscle Nerve; 2023 Jun; 67(6):515-521. PubMed ID: 36928619
[TBL] [Abstract][Full Text] [Related]
8. Inclusions in macrophages of the cerebrospinal fluid during treatment with Tofersen.
Sparasci D; Castelli C; Staedler C; Gobbi C; Ripellino P
Muscle Nerve; 2023 Feb; 67(2):E3-E5. PubMed ID: 36477882
[No Abstract] [Full Text] [Related]
9. Design of a Randomized, Placebo-Controlled, Phase 3 Trial of Tofersen Initiated in Clinically Presymptomatic SOD1 Variant Carriers: the ATLAS Study.
Benatar M; Wuu J; Andersen PM; Bucelli RC; Andrews JA; Otto M; Farahany NA; Harrington EA; Chen W; Mitchell AA; Ferguson T; Chew S; Gedney L; Oakley S; Heo J; Chary S; Fanning L; Graham D; Sun P; Liu Y; Wong J; Fradette S
Neurotherapeutics; 2022 Jul; 19(4):1248-1258. PubMed ID: 35585374
[TBL] [Abstract][Full Text] [Related]
10. ALS antisense drug falters in phase III.
Mullard A
Nat Rev Drug Discov; 2021 Dec; 20(12):883-885. PubMed ID: 34716445
[No Abstract] [Full Text] [Related]
11. An antisense oligonucleotide against SOD1 delivered intrathecally for patients with SOD1 familial amyotrophic lateral sclerosis: a phase 1, randomised, first-in-man study.
Miller TM; Pestronk A; David W; Rothstein J; Simpson E; Appel SH; Andres PL; Mahoney K; Allred P; Alexander K; Ostrow LW; Schoenfeld D; Macklin EA; Norris DA; Manousakis G; Crisp M; Smith R; Bennett CF; Bishop KM; Cudkowicz ME
Lancet Neurol; 2013 May; 12(5):435-42. PubMed ID: 23541756
[TBL] [Abstract][Full Text] [Related]
12. Silence superoxide dismutase 1 (SOD1): a promising therapeutic target for amyotrophic lateral sclerosis (ALS).
Abati E; Bresolin N; Comi G; Corti S
Expert Opin Ther Targets; 2020 Apr; 24(4):295-310. PubMed ID: 32125907
[No Abstract] [Full Text] [Related]
13. Oligonucleotide therapies: the future of amyotrophic lateral sclerosis treatment?
Aoki Y; Douglas AG; Wood MJ
Neurodegener Dis Manag; 2015; 5(2):93-5. PubMed ID: 25894871
[No Abstract] [Full Text] [Related]
14. Tofersen (Qalsody) for ALS.
Med Lett Drugs Ther; 2023 Jul; 65(1681):113-114. PubMed ID: 37460141
[No Abstract] [Full Text] [Related]
15. A novel nonsense
Zhan Z; Shu Y; Zhao Y; Peng J; Qin B
Amyotroph Lateral Scler Frontotemporal Degener; 2021 Nov; 22(7-8):583-584. PubMed ID: 33448235
[TBL] [Abstract][Full Text] [Related]
16. Novel behavioural characteristics of the superoxide dismutase 1 G93A (SOD1
Kreilaus F; Guerra S; Masanetz R; Menne V; Yerbury J; Karl T
Genes Brain Behav; 2020 Feb; 19(2):e12604. PubMed ID: 31412164
[TBL] [Abstract][Full Text] [Related]
17. Antisense oligonucleotides extend survival and reverse decrement in muscle response in ALS models.
McCampbell A; Cole T; Wegener AJ; Tomassy GS; Setnicka A; Farley BJ; Schoch KM; Hoye ML; Shabsovich M; Sun L; Luo Y; Zhang M; Comfort N; Wang B; Amacker J; Thankamony S; Salzman DW; Cudkowicz M; Graham DL; Bennett CF; Kordasiewicz HB; Swayze EE; Miller TM
J Clin Invest; 2018 Aug; 128(8):3558-3567. PubMed ID: 30010620
[TBL] [Abstract][Full Text] [Related]
18. Respiratory onset of amyotrophic lateral sclerosis in a pregnant woman with a novel SOD1 mutation.
Masrori P; Ospitalieri S; Forsberg K; Moens TG; Poesen K; Race V; Brännström T; Andersen PM; Thal DR; Van Damme P
Eur J Neurol; 2022 Apr; 29(4):1279-1283. PubMed ID: 35253968
[TBL] [Abstract][Full Text] [Related]
19. New mutation in the SOD1 (copper/zinc superoxide dismutase-1) gene in a Chinese amyotrophic lateral sclerosis (ALS) patient.
Cui F; Cai W; Wang Z; Ren Y; Li M; Sun Z; Huang X
Amyotroph Lateral Scler Frontotemporal Degener; 2013 Dec; 14(7-8):635-7. PubMed ID: 23889606
[TBL] [Abstract][Full Text] [Related]
20. Facial onset amyotrophic lateral sclerosis with K3E variant in the Cu/Zn superoxide dismutase gene.
Shibuya K; Sawai S; Sugiyama A; Koide M; Nishiyama A; Aoki M; Kuwabara S
Amyotroph Lateral Scler Frontotemporal Degener; 2021 Feb; 22(1-2):144-146. PubMed ID: 32729725
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
